Prolactin, Levodopa, and Migraine

Parantainen, J.

doi:10.1016/s0140-6736(75)91548-2

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1992

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…He noted high plasma levels of PRL during attacks and suggested that the reduction by the use of specific drugs might be a useful approach to treat these attacks. The release of PRL is inhibited by GABA at the anterior pituitary level (13)(14)(15)(16)(17)(18)(19)(20)(21)(22); sodium valproate may therefore inhibit PRL release and thus influence the migraine attack.…”

Section: Discussionmentioning

confidence: 99%

Sodium Valproate in The Prophylactic Treatment of Migraine: A Double-Blind Study Versus Placebo

1992

View full text Add to dashboard Cite

The efficacy of sodium valproate (Depalept) versus placebo in the treatment of migraine was evaluated in a double-blind randomized cross-over study in twenty-nine patients. The patients were divided into two groups each of which was alternately given 400 mg of sodium valproate B.I.d or placebo for eight weeks and then crossed over for an additional eight weeks. Our results show that in 86.2% of the patients sodium valproate was effective in preventing migraine or reducing the frequency, severity and duration of the attacks. In general, the drug was well tolerated and proved to be an effective treatment in migraine.

show abstract